Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852 is registered in ClinicalTrials.gov with American Society of Clinical Oncology as lead sponsor.

NCT NCT06377852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06377852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Lead sponsor
American Society of Clinical Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
October 29, 2024
Completion date
September 1, 2028
Enrollment
500 (estimated)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer